Pantoprazole Reig Jofre

Pantoprazole, the active ingredient in Pantoprazole Reig Jofre, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is used to manage conditions such as GERD, erosive esophagitis, peptic ulcer disease, and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Pantoprazole Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazole Reig Jofre is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastroesophageal reflux disease (GERD): improves symptom control and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: asymptomatic increase in hepatic transaminases. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

When using Pantoprazole Reig Jofre, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor electrolytes: prolonged therapy can affect magnesium and potassium levels. - Evaluate for infection risk: acid suppression may increase susceptibility to gastrointestinal infections. - Review concomitant medications: potential for altered absorption of drugs requiring an acidic environment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole oral suspension: decreased absorption due to reduced gastric acidity. - Atazanavir: markedly reduced plasma concentrations, compromising antiviral effect. - Clopidogrel: reduced conversion to active metabolite, potentially lowering antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: higher serum concentrations may occur, necessitating dose review.